Ocular Drug Delivery Devices Market

Chapter Outlines

Chapter 2 provides an executive summary of the insights captured during our research. It offers a high-level view on the likely evolution of the novel ocular drug delivery devices market in the short to mid-term and long term.

Chapter 3 provides a general overview of the structure of eye and its associated routes of drug administration. Additionally, it provides information on the popular ocular drug delivery systems (dendrimers, hydrogels, liposomes, nanomicelles and nanoparticles). 

Chapter 4 includes detailed assessment on  novel ocular drug delivery devices that are currently approved or are in different stages of development. It features a comprehensive analysis of novel ocular drug delivery devices with respect to type of drug delivery device (implants, inserts and punctal plugs), current status of development (marketed, phase III, phase II, phase I/II, phase I and preclinical), type of product (biodegradable and non-biodegradable), type of molecule (small molecules and biologics), target indication (glaucoma, retinal vein occlusion, postoperative ocular inflammation, non-infectious uveitis, diabetic macular edema, dry eye disease, wet age-related macular degeneration, retinal diseases, neovascular age-related macular degeneration and others) and route of administration (topical, intravitreal, intracameral, intracanalicular, implantable and subconjunctival). In addition, the chapter lists novel ocular drug delivery device developers, along with information on their respective year of establishment, company size, location of headquarters and most active players (in terms of number of devices).

Chapter 5 provides detailed case study on the available novel ocular drug delivery devices such as bionic eye, intraocular lenses, eye-drop dispensers, and others.

Chapter 6 includes detailed profiles of key players that are engaged in the development of novel ocular drug delivery devices. Each profile features a brief overview of the company (including information on year of establishment, number of employees, location of headquarters and key executives), information on technology use, respective product portfolio, recent developments and an informed future outlook.

Chapter 7 presents an in-depth analysis of completed, ongoing and planned clinical studies of various novel ocular drug delivery devices based on relevant parameters, such as trial registration year, trial recruitment status, phase of development, study design, target patient segment, target indication, type of sponsor, most active players (in terms of number of registered trials conducted) and key geographical regions.

Chapter 8 features an elaborate discussion and analysis of the various collaborations and partnerships that have been inked amongst players in this market, during the period 2012-2021 . Further, the partnership activity in this domain has been analyzed based on various parameters, such as year of partnership, type of partnership model (R&D agreements, product commercialization agreements, product development and commercialization agreements, product distribution agreements, technology licensing agreements, product development agreements, acquisitions, product licensing agreements and others), and regional distribution of the collaborations.

Chapter 9 provides details on the various investments that have been made into companies with proprietary novel ocular drug delivery devices, including seed financing, venture capital financing, capital raised from IPOs and subsequent offerings, grants and debt financing. The investment instances have been analyzed based on various relevant parameters, such as year of investment, amount invested, type of funding, most active players (in terms of number of funding instances) and type of investor.

Chapter 10 provides an in-depth over 1,100 patents filed / granted related to novel ocular drug delivery devices, till 2021. The instances have been analyzed based on various relevant parameters, such as type of patent, publication year, regional applicability, CPC symbols, emerging focus areas, type of drug delivery device, type of applicant, leading patent assignees (in terms of number of patents filed / granted), patent benchmarking and valuation.  

Chapter 11 presents an insightful market forecast analysis, highlighting the future potential of novel till the year 2030. In order to provide details on the future opportunity, our projections have been segmented across important market segments, namely [A] type of drug delivery device (implants, inserts and punctal plugs), [B] target indication (glaucoma, retinal vein occlusion, postoperative ocular inflammation, non-infectious uveitis, diabetic macular edema, dry eye disease, wet age-related macular degeneration, retinal diseases, neovascular age-related macular degeneration and others), [C] type of product (biodegradable  and non-biodegradable) and [D] key geographies (North America, Europe, Asia Pacific and rest of the world).

Chapter 12 summarizes the overall report. In this chapter, we have provided a list of key takeaways from the report, and expressed our independent opinion related to the research and analysis described in the previous chapters.

Chapter 13 provides the transcripts of interviews conducted with key stakeholders of this market. In this chapter, we have presented the details of our conversation with Eyal Sheetrit (Chief Executive Officer and President, Eximore) and Murty Vyakarnam (Chief Executive Officer and Co-founder, Oculinea).

Chapter 14 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.

Chapter 15 is an appendix, which contains the list of companies and organizations mentioned in the report.

Table Of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Structure of the Eye
3.3. Routes for Ocular Drug Delivery 
3.4. Ocular Drug Delivery Systems 
3.4.1. Dendrimers
3.4.2. Hydrogels
3.4.3. Liposomes
3.4.4. Nanomicelles
3.4.5. Nanoparticles
3.5. Concluding Remarks

4. MARKET OVERVIEW
4.1. Chapter Overview
4.2. Novel Ocular Drug Delivery Devices: Overall Market Landscape
4.2.1. Analysis by Type of Drug Delivery Device
4.2.2. Analysis by Current Status of Development
4.2.3. Analysis by Type of Drug Delivery Device and Current Status of Development
4.2.4. Analysis by Type of Product
4.2.5. Analysis by Type of Drug Delivery Device and Type of Product
4.2.6. Analysis by Type of Molecule
4.2.7. Analysis by Target Indication
4.2.8. Analysis by Route of Administration

4.3. Novel Ocular Drug Delivery Devices: Developer Landscape
4.3.1. Analysis by Year of Establishment
4.3.2. Analysis by Company Size
4.3.3. Analysis by Location of Headquarters
4.3.4. Key Industry Players: Analysis by Number of Devices

5. CASE STUDY: TYPES OF NOVEL OCULAR DRUG DELIVERY DEVICES
5.1. Chapter Overview
5.2. Novel Ocular Drug Delivery Devices
5.2.1. Bionic Eye
5.2.1.1. Working of a Bionic Eye

5.2.2. Intra Ocular Lenses
5.2.2.1. Evolution of Intra Ocular Lenses
5.2.2.2. Applications of Intra Ocular Lenses
5.2.2.3. Types of Intra Ocular Lenses
5.2.2.4. Classification of Intra Ocular Lenses

5.2.3. Eye Drop Dispenser Devices
5.3. Other Novel Ocular Drug Delivery Systems

6. COMPANY PROFILES
6.1. Chapter Overview
6.2. Alimera Sciences
6.2.1. Company Overview
6.2.2. Technology Overview
6.2.3. Product Portfolio
6.2.4. Recent Developments and Future Outlook

6.3. Bausch and Lomb
6.3.1. Company Overview
6.3.2. Technology Overview
6.3.3. Product Portfolio
6.3.4. Recent Developments and Future Outlook

6.4. EyePoint Pharmaceuticals
6.4.1. Company Overview
6.4.2. Technology Overview 
6.4.3. Product Portfolio
6.4.4. Recent Developments and Future Outlook

6.5. Genentech
6.5.1. Company Overview
6.5.2. Technology Overview
6.5.3. Product Portfolio
6.5.4. Recent Developments and Future Outlook

6.6. Glaukos
6.6.1. Company Overview
6.6.2. Technology Overview
6.6.3. Product Portfolio
6.6.4. Recent Developments and Future Outlook

6.7. Neurotech Pharmaceuticals
6.7.1. Company Overview
6.7.2. Technology Overview
6.7.3. Product Portfolio
6.7.4. Recent Developments and Future Outlook

6.8. Ocular Therapeutix
6.8.1. Company Overview
6.8.2. Technology Overview
6.8.3. Product Portfolio
6.8.4. Recent Developments and Future Outlook

7. CLINICAL TRIAL ANALYSIS
7.1. Chapter Overview
7.2. Scope and Methodology
7.3. Novel Ocular Drug Delivery Devices: Clinical Trial Analysis
7.3.1. Analysis by Trial Registration Year
7.3.2 Analysis by Trial Phase
7.3.3. Analysis by Trial Recruitment Status
7.3.4. Analysis by Trial Registration Year and Enrolled Patient Population
7.3.5. Analysis by Enrolled Patient Population and Phase of Development
7.3.6. Analysis by Study Design
7.3.7. Analysis by Target Patient Segment
7.3.8. Analysis by Target Indication
7.3.9. Analysis by Type of Sponsor
7.3.10. Most Active Players: Analysis by Number of Registered Trials
7.3.11. Analysis by Number of Registered Trials and Geography

8. PARTNERSHIPS AND COLLABORATIONS
8.1. Chapter Overview
8.2. Partnership Models
8.3. Novel Ocular Drug Delivery Devices: Partnerships and Collaborations
8.3.1. Analysis by Year of Partnership
8.3.2. Analysis by Type of Partnership
8.3.3. Analysis by Year and Type of Partnership
8.3.4. Most Active Players: Analysis by Number of Partnerships
8.3.5. Analysis by Geography
8.3.5.1. Region-wise Distribution
8.3.5.2. Country-wise Distribution

9. FUNDING AND INVESTMENT ANALYSIS
9.1. Chapter Overview
9.2. Type of Funding
9.3. Novel Ocular Drug Delivery Devices Market: Funding and Investment Analysis
9.3.1. Analysis by Year of Investment
9.3.2. Analysis by Amount Invested
9.3.3. Analysis by Type of Funding
9.3.4. Analysis of Amount Invested by Type of Funding 
9.3.5. Most Active Players: Analysis by Number of Funding Instances
9.3.6. Analysis by Type of Investor
9.3.7. Most Active Investors: Analysis by Number of Funding Instances
9.3.8. Analysis by Geography

10. PATENT ANALYSIS
10.1. Chapter Overview
10.2. Scope and Methodology
10.3. Novel Ocular Drug Delivery Devices: Patent Analysis
10.3.1. Analysis by Publication Year
10.3.2. Analysis by Geography
10.3.3. Analysis by CPC Symbols
10.3.4 Emerging Focus Areas
10.3.5. Analysis by Type of Drug Delivery Device
10.3.6. Analysis by Type of Applicant
10.3.7. Leading Players: Analysis by Number of Patents

10.4. Novel Ocular Drug Delivery Devices: Patent Benchmarking Analysis
10.4.1 Analysis by Patent Characteristics
10.5. Novel Ocular Drug Delivery Devices: Patent Valuation Analysis
10.6. Leading Patents: Analysis by Number of Citations

11. MARKET SIZING AND OPPORTUNITY ANALYSIS
11.1. Chapter Overview
11.2. Forecast Methodology and Key Assumptions
11.3. Global Novel Ocular Drug Delivery Devices Market, 2021-2030
11.3.1. Novel Ocular Drug Delivery Devices Market, 2021-2030: Distribution by Type of Drug Delivery Device
11.3.1.1. Novel Ocular Drug Delivery Devices Market for Implants, 2021-2030
11.3.1.2. Novel Ocular Drug Delivery Devices Market for Inserts, 2021-2030
11.3.1.3. Novel Ocular Drug Delivery Devices Market for Punctal Plugs, 2021-2030

11.3.2. Novel Ocular Drug Delivery Devices Market, 2021-2030: Distribution by Target Indication

11.3.3. Novel Ocular Drug Delivery Devices Market, 2021-2030: Distribution by Type of Product
11.3.4. Novel Ocular Drug Delivery Devices Market, 2021-2030: Distribution by Geography
11.3.4.1. Novel Ocular Drug Delivery Devices Market in North America, 2021-2030
11.3.4.1.1. Novel Ocular Drug Delivery Devices Market for Implants in North America, 2021-2030
11.3.4.1.2. Novel Ocular Drug Delivery Devices Market for Inserts in North America, 2021-2030
11.3.4.1.3. Novel Ocular Drug Delivery Devices Market for Punctal Plugs in North America, 2021-2030

11.3.4.2. Novel Ocular Drug Delivery Devices Market in Europe, 2021-2030
11.3.4.2.1. Novel Ocular Drug Delivery Devices Market for Implants in Europe, 2021-2030
11.3.4.2.2. Novel Ocular Drug Delivery Devices Market for Inserts in Europe, 2021-2030
11.3.4.2.3. Novel Ocular Drug Delivery Devices Market for Punctal Plugs in Europe, 2021-2030

11.3.4.3. Novel Ocular Drug Delivery Devices Market in Asia Pacific, 2021-2030
11.3.4.3.1. Novel Ocular Drug Delivery Devices Market for Implants in Asia Pacific, 2021-2030
11.3.4.3.2. Novel Ocular Drug Delivery Devices Market for Inserts in Asia Pacific, 2021-2030
11.3.4.3.3. Novel Ocular Drug Delivery Devices Market for Punctal Plugs in Asia Pacific, 2021-2030

11.3.4.4. Novel Ocular Drug Delivery Devices Market Rest of the World, 2021-2030
11.3.4.4.1. Novel Ocular Drug Delivery Devices Market for Implants in Rest of the World, 2021-2030
11.3.4.4.2. Novel Ocular Drug Delivery Devices Market for Inserts in Rest of the World, 2021-2030
11.3.4.4.3. Novel Ocular Drug Delivery Devices Market for Punctal Plugs in Rest of the World, 2021-2030

12. CONCLUDING REMARKS

13. EXECUTIVE INSIGHTS
13.1. Chapter Overview
13.2. Eximore
13.2.1. Company Snapshot
13.2.2. Interview Transcript: Eyal Sheetrit, Co-Founder and Chief Executive Officer

13.3. Oculinea
13.3.1. Company Snapshot
13.3.2. Interview Transcript: Murty Vyakarnam, Co-Founder and Chief Executive  
Officer 

14. APPENDIX 1: TABULATED DATA

15. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

Figure 2.1 Executive Summary: Overview of Market Landscape and Developer Landscape
Figure 2.2 Executive Summary: Clinical Trial Activity and Partnership Activity
Figure 2.3 Executive Summary: Funding and Investment Analysis and Patent Analysis
Figure 2.4 Executive Summary: Market Forecast
Figure 3.1 Structure of the Eye
Figure 3.2 Layers of Tissues in the Eye
Figure 3.3 Types of Ocular Drug Delivery Systems
Figure 3.4 Marketed Ocular Drug Delivery Implants
Figure 4.1 Novel Ocular Drug Delivery Devices: Distribution by Type of Drug Delivery Device
Figure 4.2 Novel Ocular Drug Delivery Devices: Distribution by Current Status of Development
Figure 4.3 Novel Ocular Drug Delivery Devices: Distribution by Type of Drug Delivery Device and Current Status of Development
Figure 4.4 Novel Ocular Drug Delivery Devices: Distribution by Type of Product
Figure 4.5 Novel Ocular Drug Delivery Devices: Distribution by Type of Drug Delivery Device and Type of Product
Figure 4.6 Novel Ocular Drug Delivery Devices: Distribution by Type of Molecule
Figure 4.7 Novel Ocular Drug Delivery Devices: Distribution by Target Indication
Figure 4.8 Novel Ocular Drug Delivery Devices: Distribution by Route of Administration
Figure 4.9 Novel Ocular Drug Delivery Device Developers: Distribution by Year of Establishment
Figure 4.10 Novel Ocular Drug Delivery Device Developers: Distribution by Company Size
Figure 4.11 Novel Ocular Drug Delivery Device Developers: Distribution by Location of Headquarters
Figure 4.12 Key Industry Players: Distribution by Number of Devices
Figure 5.1 Bionic Eye: External and Implantable Modules
Figure 5.2 Visual Prosthesis: Mode of Operation
Figure 5.3 Evolution of Intraocular Lenses
Figure 5.4 Applications of Bandage Intraocular Lenses
Figure 7.1 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year, Pre-2011-2021
Figure 7.2 Clinical Trial Analysis: Distribution by Phase of Development
Figure 7.3 Clinical Trial Analysis: Distribution by Trial Recruitment Status
Figure 7.4 Clinical Trial Analysis: Distribution by Trial Registration Year and Recruitment Status, Pre-2011 - 2021
Figure 7.5 Clinical Trial Analysis: Distribution by Trial Registration Year and Enrolled Patient Population
Figure 7.6 Clinical Trial Analysis: Distribution by Enrolled Patient Population and Phase of Development
Figure 7.7 Clinical Trial Analysis: Distribution by Study Design
Figure 7.8 Clinical Trial Analysis: Distribution by Target Patient Segment
Figure 7.9 Clinical Trial Analysis: Distribution by Target Indication
Figure 7.10 Clinical Trial Analysis: Distribution by Type of Sponsor
Figure 7.11 Most Active Players: Distribution by Number of Registered Trials
Figure 7.12 Clinical Trial Analysis: Distribution by Geography
Figure 8.1 Partnerships and Collaborations: Cumulative Distribution by Year, 2012-2021
Figure 8.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 8.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Figure 8.4 Most Active Players: Distribution by Number of Partnerships
Figure 8.5 Partnerships and Collaborations: Distribution by Region
Figure 8.6 Partnerships and Collaborations: Distribution by Country
Figure 9.1 Funding and Investment Analysis: Cumulative Year-wise Trend of Funding Instances, Pre-2011-2021
Figure 9.2 Funding and Investment Analysis: Cumulative Distribution of Amount Invested by Year (USD Million)
Figure 9.3 Funding and Investment Analysis: Distribution by Type of Funding
Figure 9.4 Funding and Investment Analysis: Distribution by Total Amount Invested and Type of Funding (USD Million)
Figure 9.5 Funding and Investment Analysis: Heat-map Representation of Amount Invested and Type of Funding (USD Million)
Figure 9.6 Most Active Players: Distribution by Number of Funding Instances
Figure 9.7 Funding and Investment Analysis: Distribution by Type of Investor
Figure 9.8 Most Active Investors: Distribution by Number of Funding Instances
Figure 9.9 Funding and Investment Analysis: Distribution by Geography
Figure 10.1 Patent Analysis: Distribution by Patent Filed
Figure 10.2 Patent Analysis: Distribution by Year of Publication, 2002-2021
Figure 10.3 Patent Analysis: Distribution by Location of Patent Jurisdiction
Figure 10.4 Patent Analysis: Distribution by Jurisdiction
Figure 10.5 Patent Analysis: Distribution by CPC Symbols
Figure 10.6 Patent Analysis: Emerging Focus Areas
Figure 10.7 Patent Analysis: Distribution by Type of Drug Delivery Device
Figure 10.8 Patent Analysis: Cumulative Year-wise Distribution by Type of Applicant
Figure 10.9 Leading Industry Players: Distribution by Number of Patents
Figure 10.10 Leading Non-Industry Players: Distribution by Number of Patents
Figure 10.11 Leading Patent Assignees: Distribution by Number of Patents
Figure 10.12 Patent Benchmarking Analysis: Distribution of Leading Industry Player by Patent Characteristics (CPC Symbols)
Figure 10.13 Patent Analysis: Distribution by Patent Age
Figure 10.14 Novel Ocular Drug Delivery Devices: Patent Valuation
Figure 11.1 Global Novel Ocular Drug Delivery Devices Market, 2021-2030 (USD Million)
Figure 11.2 Novel Ocular Drug Delivery Market for Implants, 2021-2030 (USD Million)
Figure 11.3 Novel Ocular Drug Delivery Market for Inserts, 2021-2030 (USD Million)
Figure 11.4 Novel Ocular Drug Delivery Market for Punctal Plugs, 2021-2030 (USD Million)
Figure 11.5 Novel Ocular Drug Delivery Devices Market, 2021 and 2030: Distribution by Target Indication (USD Million)
Figure 11.6 Novel Ocular Drug Delivery Devices Market, 2021 and 2030: Distribution by Type of Product (USD Million)
Figure 11.7 Novel Ocular Drug Delivery Devices Market, 2021 and 2030: Distribution by Geography (USD Million)
Figure 11.8 Novel Ocular Drug Delivery Devices Market in North America, 2021-2030 (USD Million)
Figure 11.9 Novel Ocular Drug Delivery Devices Market for Implants in North America, 2021-2030 (USD Million)
Figure 11.10 Novel Ocular Drug Delivery Devices Market for Inserts in North America, 2021-2030 (USD Million)
Figure 11.11 Novel Ocular Drug Delivery Devices Market for Punctal Plugs in North America, 2021-2030 (USD Million)
Figure 11.12 Novel Ocular Drug Delivery Devices Market in Europe, 2021-2030 (USD Million)
Figure 11.13 Novel Ocular Drug Delivery Devices Market for Implants in Europe, 2021-2030 (USD Million)
Figure 11.14 Novel Ocular Drug Delivery Devices Market for Inserts in Europe, 2021-2030 (USD Million)
Figure 11.15 Novel Ocular Drug Delivery Devices Market for Punctal Plugs in Europe, 2021-2030 (USD Million)
Figure 11.16 Novel Ocular Drug Delivery Devices Market in Asia Pacific, 2021-2030 (USD Million)
Figure 11.17 Novel Ocular Drug Delivery Devices Market for Implants in Asia Pacific, 2021-2030 (USD Million)
Figure 11.18 Novel Ocular Drug Delivery Devices Market for Inserts in Asia Pacific, 2021-2030 (USD Million)
Figure 11.19 Novel Ocular Drug Delivery Devices Market for Punctal Plugs in Asia Pacific, 2021-2030 (USD Million)
Figure 11.20 Novel Ocular Drug Delivery Devices Market in Rest of the World, 2021-2030 (USD Million)
Figure 11.21 Novel Ocular Drug Delivery Devices Market for Implants in Rest of the World, 2021-2030 (USD Million)
Figure 11.22 Novel Ocular Drug Delivery Devices Market for Inserts in Rest of the World, 2021-2030 (USD Million)
Figure 11.23 Novel Ocular Drug Delivery Devices Market for Punctal Plugs in Rest of the World, 2021-2030 (USD Million)
Figure 12.1 Concluding Remarks: Overall Market Landscape
Figure 12.2 Concluding Remarks: Clinical Trial Analysis
Figure 12.3 Concluding Remarks: Partnerships and Collaborations
Figure 12.4 Concluding Remarks: Funding and Investment Analysis
Figure 12.5 Concluding Remarks: Market Forecast

List Of Tables

Table 3.1 Routes for Ocular Drug Delivery
Table 4.1 Novel Ocular Drug Delivery: Overall Market Landscape
Table 4.2 Novel Ocular Drug Delivery Devices: List of Developers
Table 5.1 Bionic Eye Systems: Information on Device Developer, Headquarters, Target Indication and Site of Implant Placement
Table 5.2 Advantages and Disadvantages of Different Types of Intraocular Lenses
Table 5.3 Therapeutic Intraocular Lenses: Information on Developer, Headquarters, Target Indication and Type of product
Table 5.4 Eye-Drop Dispenser Devices: Information on Developer, Headquarters and Target Site
Table 5.5 Other Novel Ocular Drug Delivery Devices: Information on Technology, Type of Product, Developer, Year of Establishment, Company Size and Headquarters
Table 6.1 List of Companies Profiled
Table 6.2 Alimera Sciences: Company Overview
Table 6.3 Alimera Sciences: Technology Overview
Table 6.4 Alimera Sciences: Product Portfolio
Table 6.5 Alimera Sciences: Recent Developments and Future Outlook
Table 6.6 Bausch and Lomb: Company Overview
Table 6.7 Bausch and Lomb: Technology Overview
Table 6.8 Bausch and Lomb: Product Portfolio
Table 6.9 Bausch and Lomb: Recent Developments and Future Outlook
Table 6.10 EyePoint Pharmaceuticals: Company Overview
Table 6.11 EyePoint Pharmaceuticals: Technology Overview
Table 6.12 EyePoint Pharmaceuticals: Product Portfolio
Table 6.13 EyePoint Pharmaceuticals: Recent Developments and Future Outlook
Table 6.14 Genentech: Company Overview
Table 6.15 Genentech: Technology Overview
Table 6.16 Genentech: Product Portfolio
Table 6.17 Glaukos: Company Overview
Table 6.18 Glaukos: Technology Overview
Table 6.19 Glaukos: Product Portfolio
Table 6.20 Glaukos: Recent Developments and Future Outlook
Table 6.21 Neurotech Pharmaceuticals: Company Overview
Table 6.22 Neurotech Pharmaceuticals: Technology Overview
Table 6.23 Neurotech Pharmaceuticals: Product Portfolio
Table 6.24 Ocular Therapeutix: Company Overview
Table 6.25 Ocular Therapeutix: Technology Overview
Table 6.26 Ocular Therapeutix: Product Portfolio
Table 6.27 Ocular Therapeutix: Recent Developments and Future Outlook
Table 7.1 Novel Ocular Drug Delivery Devices: List of Clinical Trials
Table 8.1 Novel Ocular Drug Delivery Devices: List of Partnerships and Collaborations, 2012-2021
Table 9.1 Novel Ocular Drug Delivery Devices: Funding and Investments, Pre-2011-2021
Table 9.2 Novel Ocular Drug Delivery Devices: Summary of Investments
Table 10.1 Patent Analysis: Prominent CPC Symbols
Table 10.2 Patent Analysis: Most Popular CPC Symbols
Table 10.3 Patent Analysis: List of Top CPC Symbols
Table 10.4 Patent Analysis: Summary of Benchmarking Analysis
Table 10.5 Patent Analysis: Categorization based on Weighted Valuation Scores
Table 10.6 Patent Portfolio: List of Leading Patents (In terms of Highest Relative Valuation)
Table 10.7 Patent Portfolio: List of Leading Patents (In terms of Number of Citations)
Table 13.1 Eximore: Company Snapshot
Table 13.2 Oculinea: Company Snapshot
Table 14.1 Novel Ocular Drug Delivery Devices: Distribution by Type of Drug Delivery Device
Table 14.2 Novel Ocular Drug Delivery Devices: Distribution by Current Status of Development
Table 14.3 Novel Ocular Drug Delivery Devices: Distribution by Type of Drug Delivery Device and Current Status of Development
Table 14.4 Novel Ocular Drug Delivery Devices: Distribution by Type of Product
Table 14.5 Novel Ocular Drug Delivery Devices: Distribution by Type of Drug Delivery Device and Type of Product
Table 14.6 Novel Ocular Drug Delivery Devices: Distribution by Type of Molecule
Table 14.7 Novel Ocular Drug Delivery Devices: Distribution by Target Indication
Table 14.8 Novel Ocular Drug Delivery Devices: Distribution by Route of Administration
Table 14.9 Novel Ocular Drug Delivery Device Developers: Distribution by Year of Establishment
Table 14.10 Novel Ocular Drug Delivery Device Developers: Distribution by Company Size
Table 14.11 Novel Ocular Drug Delivery Device Developers: Distribution by Location of Headquarters
Table 14.12 Key Industry Players: Distribution by Number of Devices
Table 14.13 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year, Pre-2011-2021
Table 14.14 Clinical Trial Analysis: Distribution by Phase of Development
Table 14.15 Clinical Trial Analysis: Distribution by Trial Recruitment Status
Table 14.16 Clinical Trial Analysis: Distribution by Trial Registration Year and Recruitment Status, Pre-2011-2021
Table 14.17 Clinical Trial Analysis: Distribution by Trial Registration Year and Enrolled Patient Population
Table 14.18 Clinical Trial Analysis: Distribution by Enrolled Patient Population and Phase of Development
Table 14.19 Clinical Trial Analysis: Distribution by Study Design
Table 14.20 Clinical Trial Analysis: Distribution by Target Patient Segment
Table 14.21 Clinical Trial Analysis: Distribution by Target Indication
Table 14.22 Clinical Trial Analysis: Distribution by Type of Sponsor
Table 14.23 Most Active Players: Distribution by Number of Registered Trials
Table 14.24 Clinical Trial Analysis: Distribution by Geography
Table 14.25 Partnerships and Collaborations: Cumulative Distribution by Year, 2012-2021
Table 14.26 Partnerships and Collaborations: Distribution by Type of Partnership
Table 14.27 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Table 14.28 Most Active Players: Distribution by Number of Partnerships
Table 14.29 Partnerships and Collaborations: Distribution by Region
Table 14.30 Partnerships and Collaborations: Distribution by Country
Table 14.31 Funding and Investment Analysis: Cumulative Year-wise Trend of Funding Instances, Pre-2011-2021
Table 14.32 Funding and Investment Analysis: Cumulative Distribution by Amount Invested and Year (USD Million)
Table 14.33 Funding and Investment Analysis: Distribution by Type of Funding
Table 14.34 Funding and Investment Analysis: Distribution by Total Amount Invested and Type of Funding (USD Million)
Table 14.35 Funding and Investment Analysis: Heat-map Representation of Amount Invested and Type of Funding, Pre-2011-2021(USD Million)
Table 14.36 Most Active Players: Distribution by Number of Funding Instances
Table 14.37 Funding and Investment Analysis: Distribution by Type of Investor
Table 14.38 Most Active Investors: Distribution by Number of Funding Instances
Table 14.39 Funding and Investment Analysis: Distribution by Geography
Table 14.40 Patent Analysis: Distribution by Type of Patent
Table 14.41 Patent Analysis: Distribution by Year of Publication, 2002-2021
Table 14.42 Patent Analysis: Distribution by Geography
Table 14.43 Patent Analysis: Distribution by Jurisdiction
Table 14.44 Patent Analysis: Distribution by CPC Symbols
Table 14.45 Patent Analysis: Distribution by Type of Drug Delivery Device
Table 14.46 Patent Analysis: Cumulative Year-wise Distribution by Type of Applicant
Table 14.47 Leading Industry Players: Distribution by Number of Patents
Table 14.48 Leading Non-Industry Players: Distribution by Number of Patents
Table 14.49 Leading Patent Assignees: Distribution by Number of Patents
Table 14.50 Patent Analysis: Distribution by Patent Age
Table 14.51 Novel Ocular Drug Delivery Devices: Patent Valuation
Table 14.52 Global Novel Ocular Drug Delivery Devices Market, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 14.53 Novel Ocular Drug Delivery Market for Implants, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 14.54 Novel Ocular Drug Delivery Market for Inserts, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 14.55 Novel Ocular Drug Delivery Market for Punctal Plugs, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 14.56 Novel Ocular Drug Delivery Devices Market, 2021 and 2030: Distribution by Target Indication (USD Million)
Table 14.57 Novel Ocular Drug Delivery Devices Market, 2021 and 2030: Distribution by Type of Product (USD Million)
Table 14.58 Novel Ocular Drug Delivery Devices Market, 2021 and 2030: Distribution by Geography (USD Million)
Table 14.59 Novel Ocular Drug Delivery Devices Market in North America, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 14.60 Novel Ocular Drug Delivery Devices Market for Implants in North America, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 14.61 Novel Ocular Drug Delivery Devices Market for Inserts in North America, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 14.62 Novel Ocular Drug Delivery Devices Market for Punctal Plugs in North America, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 14.63 Novel Ocular Drug Delivery Devices Market in Europe, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 14.64 Novel Ocular Drug Delivery Devices Market for Implants in Europe, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 14.65 Novel Ocular Drug Delivery Devices Market for Inserts in Europe, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 14.66 Novel Ocular Drug Delivery Devices Market for Punctal Plugs in Europe, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 14.67 Novel Ocular Drug Delivery Devices Market in Asia Pacific, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 14.68 Novel Ocular Drug Delivery Devices Market for Implants in Asia Pacific, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 14.69 Novel Ocular Drug Delivery Devices Market for Inserts in Asia Pacific, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 14.70 Novel Ocular Drug Delivery Devices Market for Punctal Plugs in Asia Pacific, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 14.71 Novel Ocular Drug Delivery Devices Market in Rest of the World, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 14.72 Novel Ocular Drug Delivery Devices Market for Implants in Rest of the World, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 14.73 Novel Ocular Drug Delivery Devices Market for Inserts in Rest of the World, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 14.74 Novel Ocular Drug Delivery Devices Market for Punctal Plugs in Rest of the World, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)

List Of Companies

The following companies and organizations have been mentioned in the report.

1. 20/20 OptimEyes Technologies
2. 23andMe
3. Aciont
4. AcuFocus 
5. Adaptive Biotechnologies
6. Aerie Pharmaceuticals
7. Aero Pump
8. AffaMed Therapeutics
9. Akarna Therapeutics
10. Alcon
11. Alcon
12. Alibaba Health Information Technology
13. Alimera Sciences
14. Allergan
15. Alta Partners
16. Amorphex Therapeutics
17. Angiotech Pharmaceuticals
18. Anthrogenesis
19. Ascension Ventures
20. Atalanta
21. Avedro
22. Avizorex Pharma 
23. Bausch & Lomb
24. Brien Holden Vision Institute (BHVI)
25. BioHealthWays 
26. Bionic Vision Technologies
27. Brandon Capital partners 
28. BTG 
29. Burrill & Company
30. Cella Therapeutics
31. Children's National Hospital
32. ChromaGen Vision
33. Cirle
34. Clarus Ventures
35. Clearside Biomedical
36. Corporate Renaissance Group
37. D. Western Therapeutics Institute
38. Deerfield
39. DelSiTech
40. Department of Defense
41. Domain Associates
42. DSM 
43. Envisia Therapeutics
44. Escalon Medical
45. EW Healthcare Partners
46. Eximore
47. EYE-GO
48. EyePoint Pharmaceuticals
49. Eyevensys
50. FB VISION
51. Fjord Ventures
52. Foundry Therapeutics 
53. Frazier Healthcare Partners
54. Genentech
55. Genesis Therapeutics
56. Glaukos
57. Graybug Vision
58. Gund Investment
59. Gyroscope Therapeutics
60. Heptares Therapeutics
61. Horizon Discovery 
62. Horus Pharma
63. IDVentures
64. IDA Ireland
65. Imbio
66. ImprimisRx 
67. Incept
68. InterWest Partners
69. Intratus
70. Invest Michigan
71. IQVIA
72. Johnson & Johnson Vision
73. Kala Pharmaceuticals
74. Kedalion Therapeutics
75. Kineta
76. Knight Therapeutics
77. Kodiak Sciences
78. Laboratoires Thea
79. Laurus Labs 
80. LayerBio 
81. Lodo Therapeutics
82. M25
83. Mati Therapeutics
84. MEAgate
85. Medical Research Commercialisation Fund (MRCF)
86. Medis
87. Merck
88. Mercury Fund
89. Meritech Capital Partners
90. Microchip Technology 
91. Micropore Technologies
92. MilliporeSigma
93. Modulight
94. Monash Vision Group
95. Montreaux Growth Partners
96. MuPharma
97. Mystic Pharmaceuticals
98. Nanomerics
99. Nanyang Technological University
100. National Institutes of Health (NIH)
101. Nemera
102. Neurotech Pharmaceuticals
103. Nicox
104. Novaer 
105. Novaliq
106. Novartis
107. NuMedii 
108. Occlugel
109. Ocular Therapeutix
110. Oculex Pharmaceuticals 
111. Ocumension Therapeutics
112. Oncimmune
113. OneOncology
114. Opharmic Technology
115. OPHTEC
116. OrbiMed Advisors
117. Orsini Specialty Pharmacy
118. Osage University Partners
119. Paris Diderot University
120. PatientFi
121. Pieris Pharmaceuticals
122. Pixium Vision
123. Polaris Partners
124. PolyActiva  
125. PSIMedica  
126. Purdue Pharma
127. QLT Plug Delivery 
128. Quadra Logic Tech
129. Qura
130. Ramot at Tel Aviv University
131. Ramscor  
132. Quadra Logic Technologies 
133. Re-Vana Therapeutics 
134. Red Cedar Ventures
135. Redwood Pharma
136. Regeneron
137. Relay Therapeutics
138. Ribometrix
139. Ripple Therapeutics
140. Roche
141. Rosalind Advisors
142. Rugen Therapeutics
143. S K Pharmaceuticals 
144. Santen Pharmaceutical
145. Second Sight
146. Societa Industria Farmaceutica Italiana (SIFI)
147. Sofinnova Ventures
148. Sparta Systems
149. SpringTime Ventures
150. STADA Arzneimittel
151. Sun Ophthalmics
152. SurModics
153. Sustained Nano Systems
154. SV Life Sciences
155. SWK Holdings Corporation
156. Taiwan Liposome Company
157. TALLC
158. TARGET PharmaSolutions
159. Tempest Therapeutics 
160. TerraCycle 
161. TPG Capital
162. The French National Centre for Scientific Research
163. Théa Open Innovation
164. TheraKine 
165. Tufts University
166. UCL Business
167. University of Arizona
168. University of California
169. University of California
170. University of Cincinnati
171. University of Coimbra
172. University of Colorado Board of Regents
173. University of Illinois
174. University of Maryland
175. University of Michigan 
176. University of Northwestern
177. University of Pennsylvania
178. University of Pittsburgh 
179. University of the Witwatersrand
180. Versant Ventures
181. ViSci
182. Vision Source
183. Visionex Technologies
184. X Chem
185. Yuuwa Capital

Source 1: cdn.who.int/media/docs/default-source/infographics-pdf/world-vision-infographic-final.pdf?sfvrsn=85b7bcde_2
Source 2: www.sysrevpharm.org/articles/ophthalmic-drug-delivery-system-challenges-and-approaches.pdf